论文部分内容阅读
目的探讨GSTM1及GSTT1基因多态性与子宫内膜癌发生发展的关系。方法以医院为基础,采用多重差别PCR技术检测2006年5月至2008年5月于河北医科大学第四医院经手术治疗的171例子宫内膜癌患者(研究组)和同期201例健康女性(对照组)的GSTM1和GSTT1基因型。结果 GSTM1基因缺失频率研究组与对照组相比差异无统计学意义(P=0.168);研究组GSTT1非缺失基因型频率为59.1%,显著高于对照组45.8%,差异有统计学意义(P=0.011);叉生分析表明,GSTT1非缺失基因型与子宫内膜癌的关联大于GSTM1缺失基因型,两者在子宫内膜癌发生中存在协同作用。初潮年龄<15岁时,研究组中GSTT1非缺失基因型频率明显高于对照组(P=0.011);已绝经的研究组中GSTT1非缺失基因型频率明显高于对照组(P=0.013)。结论 GSTT1非缺失基因型增加了子宫内膜癌的易感性,如同时合并GSTM1缺失基因,则这种危险性增加。初潮年龄早,或已绝经的个体,携带GSTT1非缺失基因型者易感子宫内膜癌。
Objective To investigate the relationship between GSTM1 and GSTT1 gene polymorphisms and the occurrence and development of endometrial carcinoma. Methods Based on the hospital, 171 cases of endometrial cancer (study group) and 201 healthy women (control group) who underwent surgery in the Fourth Hospital of Hebei Medical University from May 2006 to May 2008 were examined by using multiplex PCR. Control group) of GSTM1 and GSTT1 genotypes. Results There was no significant difference in the frequency of GSTM1 deletion between the study group and the control group (P = 0.168). The frequency of GSTT1 non-deletion genotype was 59.1% in the study group, which was significantly higher than that in the control group (P = 0.011). The cross-over analysis showed that the association between GSTT1 non-deletion genotypes and endometrial cancer was greater than that of GSTM1 deletion genotypes, both of which had synergistic effect in the pathogenesis of endometrial carcinoma. The frequencies of non-deletion genotypes of GSTT1 in the study group were significantly higher than those in the control group (P = 0.011) when the menarche age was <15 years old. The frequencies of non-deletion genotypes of GSTT1 in the menopausal study group were significantly higher than those in the control group (P = 0.013). Conclusion The non-deletion genotype of GSTT1 increased the susceptibility of endometrial carcinoma, and the simultaneous increase of GSTM1 deletion gene increased the risk. Early menarche or postmenopausal individuals with GSTT1 non-deletion genotype susceptible to endometrial cancer.